Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

h and

development 3,754 (3,754) - - -

Other (income)/

expense, net (231) - 255 - 24

Special and acquisition

related charges 52 - (52) - -

Equity income (566) - - - (566)

(Loss)/income before

income taxes (3,340) 4,080 (203) 21 558

Income tax (benefit)/

expense (14) 89 2 1 78

Net (loss)/income

before cumulative

effect of a change

in accounting

principle $(3,326) $3,991 $(205) $20 $480

Cumulative effect

of a change in

accounting

principle, net

of tax - - - - -

Net (loss)/income $(3,326) $3,991 $(205) $20 $480

Preferred stock

dividends 38 - - - 38

Net (loss)/income

available to

common

shareholders $(3,364) $3,991 $(205) $20 $442

Diluted (loss)/

earnings per

common share:

(Loss)/earnings

available to

common

shareholders

before cumulative

effect of a change

in accounting

principle $ (2.08) $0.27

Cumulative effect

of a change in

accounting

principle, net

of tax - -

Diluted (loss)/

earnings per

common share $ (2.08) $0.27

Average common

shares outstanding

-diluted 1,621 1,648

SCHERING-PLOUGH CORPORATION

Re
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), ... of regenerative medicine, announced today that it will ... investors on Tuesday, July 29, 2014, at 4:30 ... include an overview of Asterias, business strategy and ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before ...
(Date:7/24/2014)... yet to materialise. Yet, scientists are making progress ... faster. One such approach relies on quantum dotsa ... an electric field. A new study demonstrates that ... dots (TQDs) with electrical impulses can help better ... TQDs be used as quantum information units, which ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Germany and MINNEAPOLIS, Minnesota, February 11, Bayer HealthCare ... Minneapolis, MN, (Nasdaq: POSS ), announced today ... pursuant to which,MEDRAD will acquire Possis Medical in ... or a total equity value of approximately US-Dollar ...
... Feb. 11 Replikins Ltd. announced that the,quantitative ... structure,predicts that the current H5N1 cycle is over. ... and high mortality characteristics,are expected to subside - ... or,another influenza virus strain begins., 140,000 virus ...
... Cryo-Cell,International, Inc. (OTC Bulletin Board Symbol: CCEL) (the ... family cord blood banks, today,announced results for fiscal ... ended November 30, 2007 were,approximately $17.5 million, up ... ended November 30, 2006. The Company reported a ...
Cached Biology Technology:Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 2Cryo-Cell International, Inc. Reports Results for Fiscal 2007 3Cryo-Cell International, Inc. Reports Results for Fiscal 2007 4Cryo-Cell International, Inc. Reports Results for Fiscal 2007 5Cryo-Cell International, Inc. Reports Results for Fiscal 2007 6
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... NJIT this week for an all-day public forum on ... Agency (EPA) to dredge toxic sediment from an eight-mile ... has called the plan, which proposes removing 4.3 million ... the riverbed, one of the largest cleanups in the ... disposed off-site. , "We need to ensure the future ...
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
Breaking Biology News(10 mins):Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... director's cut. In much the same way that numerous films ... footage, a molecular process called alternative splicing enables a single ... created by a team of researchers at Rockefeller University and ... Nature, shows for the first time how the specific location ...
... Hopkins and from the University of Milan have effectively ... in mice using a protein that selectively induces positive ... cancer stem cells. The report is published this week ... cancer-glioblastoma-is marked by the presence of these stem-cell-like brain ...
... have found that how much detail one remembers of an ... is activated to "package" the memory. , The research may ... an experience such as a car accident, and yet vividly ... , In experiments using functional magnetic resonance imaging (fMRI), the ...
Cached Biology News:RNA map provides first comprehensive understanding of alternative splicing 2RNA map provides first comprehensive understanding of alternative splicing 3RNA map provides first comprehensive understanding of alternative splicing 4Natural protein stops deadly human brain cancer in mice 2Memories: It's all in the packaging, scientists say 2
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
... large numbers of samples may be carried out ... operator attention. System control and data processing ... 4900. The elegant, powerful and very easy ... Windows 98 and 2000., The supplied detector is ...
Narrow-mouth has heavy-duty rim. Approximate graduations are in durable white enamel. Extra large marking space. capacity 125 mL Special grade: student grade...
Biology Products: